Cognitive Correlates in Amyotrophic Lateral Sclerosis: a Population-based Study in Italy
Overview
Neurosurgery
Psychiatry
Authors
Affiliations
Background: There is less data available regarding the characteristics of cognitive impairment in patients with amyotrophic lateral sclerosis (ALS) in a population-based series.
Methodology: Patients with ALS incident in Piemonte, Italy, between 2009 and 2011 underwent an extensive neuropsychological battery. Cognitive status was classified as follows: normal cognition, frontotemporal dementia (ALS-FTD), executive cognitive impairment (ALS-ECI), non-executive cognitive impairment (ALS-NECI), behavioural impairment (ALS-Bi), non-classifiable cognitive impairment. We also assessed 127 age-matched and gender-matched controls identified through patients' general practitioners.
Results: Out of the 281 incident patients, 207 (71.9%) underwent the neuropsychological testing; of these, 19 were excluded from the analysis due previous conditions affecting cognition. Ninety-one (49.7%) patients were cognitively normal, 23 (12.6%) had ALS-FTD, 36 (19.7%) ALS-ECI, 10 (5.5%) ALS-NECI, 11 (6.0%) ALS-Bi and 11 (6.0%) non-classifiable cognitive impairment, 1 had comorbid Alzheimer's disease. Patients with ALS-FTD were older, had a lower education level, and had a shorter survival than any other cognitive group. Of the nine cases with C9ORF72 mutation, six had ALS-FTD, two ALS-ECI and one was cognitively normal; one of the five patients with SOD1 mutations and one of the five patients with TARBDP mutations had ALS-Bi.
Conclusions: About 50% of Italian patients with ALS had some degree of cognitive impairment, in keeping with a previous Irish study, despite the largely different genetic background of the two populations. The lower educational attainment in patients with ALS-FTD indicated a possible role of cognitive reserve in ALS-related cognitive impairment. ALS-ECI and ALS-NECI may represent discrete cognitive syndromes in the continuum of ALS and FTD.
RNA binding proteins (RBPs) on genetic stability and diseases.
Aborode A, Abass O, Nasiru S, Eigbobo M, Nefishatu S, Idowu A Glob Med Genet. 2025; 12(1):100032.
PMID: 39925443 PMC: 11803229. DOI: 10.1016/j.gmg.2024.100032.
The role of rs671 polymorphism and C-reactive protein in the phenotypes of male ALS patients.
Huang L, Liu M, Tang J, Gong Z, Li Z, Yang Y Front Neurosci. 2024; 18:1397991.
PMID: 39290715 PMC: 11405379. DOI: 10.3389/fnins.2024.1397991.
Christidi F, Kleinerova J, Tan E, Delaney S, Tacheva A, Hengeveld J Biology (Basel). 2024; 13(7).
PMID: 39056697 PMC: 11273537. DOI: 10.3390/biology13070504.
Yang T, Wei Q, Li C, Ou R, Lin J, Cheng Y Front Neurol. 2024; 15:1405275.
PMID: 38882692 PMC: 11176427. DOI: 10.3389/fneur.2024.1405275.
Repeated cognitive assessments show stable function over time in patients with ALS.
Oijerstedt L, Foucher J, Lovik A, Yazdani S, Juto A, Klappe U J Neurol. 2024; 271(8):5267-5274.
PMID: 38853167 PMC: 11319384. DOI: 10.1007/s00415-024-12479-x.